MedRx Co., Ltd (4586.T)
- Previous Close
64.00 - Open
65.00 - Bid 64.00 x --
- Ask 65.00 x --
- Day's Range
63.00 - 66.00 - 52 Week Range
55.00 - 199.00 - Volume
629,700 - Avg. Volume
603,515 - Market Cap (intraday)
3.04B - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-13.36 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
www.medrx.co.jp22
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 4586.T
View MorePerformance Overview: 4586.T
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4586.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4586.T
View MoreValuation Measures
Market Cap
3.04B
Enterprise Value
873.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.07
Price/Book (mrq)
1.22
Enterprise Value/Revenue
3.44
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.91%
Return on Equity (ttm)
-39.40%
Revenue (ttm)
257M
Net Income Avi to Common (ttm)
-806M
Diluted EPS (ttm)
-13.36
Balance Sheet and Cash Flow
Total Cash (mrq)
1.98B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-481.62M